Ontology highlight
ABSTRACT:
SUBMITTER: Falchook GS
PROVIDER: S-EPMC4278330 | biostudies-literature | 2014
REPOSITORIES: biostudies-literature
Falchook Gerald S GS Naing Aung A Wheler Jennifer J JJ Tsimberidou Apostolia M AM Zinner Ralph R Hong David S DS Fu Siqing S Piha-Paul Sarina A SA Janku Filip F Hess Kenneth R KR Bastida Christel C Kurzrock Razelle R
Oncoscience 20140807 8
Preclinical studies demonstrate that epidermal growth factor receptor (EGFR) signals through both kinase-dependent and independent pathways and that combining a small-molecule EGFR inhibitor, EGFR antibody, and/or anti-angiogenic agent is synergistic. We conducted a dose-escalation, phase I study combining erlotinib, cetuximab, and bevacizumab. The subset of patients with metastatic colorectal cancer was analyzed for safety and antitumor activity. Forty-one patients with heavily pretreated metas ...[more]